Onivyde is a chemotherapy drug used to treat pancreatic cancer. It is a liposomal formulation of irinotecan [1].
How does Onivyde work?
Onivyde is a topoisomerase I inhibitor. It works by preventing cancer cells from dividing and growing, ultimately leading to their death [2]. The liposomal encapsulation is designed to alter the drug's distribution and potentially increase its concentration in tumors [1].
What types of pancreatic cancer is Onivyde used for?
Onivyde is indicated for patients with metastatic pancreatic adenocarcinoma whose disease has progressed following gemcitabine-based chemotherapy [2]. It is typically used in combination with other chemotherapy agents [1].
When does Onivyde's patent expire?
Information on Onivyde's patent expiration dates can be found through specialized patent tracking services like DrugPatentWatch.com [3]. Patent landscapes for complex pharmaceuticals are dynamic and can be influenced by various factors, including new formulations, manufacturing processes, and regulatory exclusivities [3].
What are the side effects of Onivyde?
Common side effects of Onivyde include diarrhea, fatigue, nausea, vomiting, decreased appetite, stomatitis, and abdominal pain [2]. Severe side effects can occur, and patients should discuss potential risks with their healthcare provider [2].
Are there alternatives to Onivyde for pancreatic cancer treatment?
Several chemotherapy regimens are used for pancreatic cancer, often depending on the stage of the disease and prior treatments. Other treatment options may include fluorouracil, leucovorin, oxaliplatin, and irinotecan (non-liposomal) [1].
Who manufactures Onivyde?
Onivyde is manufactured by Ipsen Biopharmaceuticals [4].
---
Sources:
1. https://drugpatentwatch.com/
2. [Information on Onivyde usage and side effects]
3. [Details on patent expiration]
4. [Manufacturer information]